Cargando…

Population Pharmacodynamic Modeling of Epoetin Alfa in End‐Stage Renal Disease Patients Receiving Maintenance Treatment Using Bayesian Approach

The ability to control dosage regimens of erythropoiesis‐stimulating agents (ESAs) to maintain a desired hemoglobin (HGB) target is still elusive. We utilized a Bayesian approach and informative priors to characterize HGB profiles, using simulated drug concentrations, in patients with end‐stage rena...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Ly Minh, Meaney, Calvin J., Rao, Gauri G., Panesar, Mandip, Krzyzanski, Wojciech
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577019/ https://www.ncbi.nlm.nih.gov/pubmed/32996284 http://dx.doi.org/10.1002/psp4.12556

Ejemplares similares

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
por: Fishbane, Steven, et al.
Publicado: (2019)

Epoetin Alfa: A Cause of Coronary Artery Thrombosis
por: Siddiqui, Muhammad Umer, et al.
Publicado: (2017)

Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
por: Ots, Pilar Ma Samper, et al.
Publicado: (2008)

Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of One US-Marketed and Two European-Marketed Epoetin Alfas: A Randomized Prospective Study
por: Lissy, Michael, et al.
Publicado: (2012)

Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial
por: Sörgel, Fritz, et al.
Publicado: (2009)

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon(®) and Eprex(®) following a single subcutaneous administration in healthy male volunteers
por: Yoon, Sumin, et al.
Publicado: (2017)

Critical Role of Iron in Epoetin Alfa Treatment of Chemotherapy-Associated Anemia
por: Gross, Irwin, et al.
Publicado: (2016)

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014)

Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction
por: Vullaganti, Sirish, et al.
Publicado: (2014)

Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report
por: Behler, Caroline M, et al.
Publicado: (2009)

Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study
por: Stoppa, Giovanna, et al.
Publicado: (2018)

Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study
por: Santos, E.J.F., et al.
Publicado: (2018)

Multi-scale model of drug induced adaptive resistance of Gram-negative bacteria to polymyxin B
por: Krzyzanski, Wojciech, et al.
Publicado: (2017)

Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity
por: Seidl, Andreas, et al.
Publicado: (2011)

Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients
por: Prasad, Bhanu, et al.
Publicado: (2020)

Surgical prescription of epoetin alfa in contemporary total hip arthroplasty: a prospective comparative study
por: Hourlier, Hervé, et al.
Publicado: (2019)

Successful Prolonged Desensitization to Epoetin-Alfa Hypersensitivity in an Adult Patient With Advanced Chronic Kidney Disease
por: Panchal, Hemali, et al.
Publicado: (2023)

How to Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy?
por: Hasegawa, Takahiro, et al.
Publicado: (2016)

Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial
por: Wilkinson, P M, et al.
Publicado: (2006)

TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients
por: Gaweda, Adam E, et al.
Publicado: (2014)

Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial
por: Moebus, Volker, et al.
Publicado: (2013)

Arterial and venous thrombosis complicating coronary artery bypass grafting after use of epoetin alfa-epbx
por: Murillo-Berlioz, Alejandro, et al.
Publicado: (2020)

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
por: Cremieux, Pierre Y., et al.
Publicado: (2004)

The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data
por: Pollak, Victor E, et al.
Publicado: (2009)

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial
por: Carrera, Fernando, et al.
Publicado: (2010)

Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
por: Choi, Peter, et al.
Publicado: (2013)

The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients
por: AlKharboush, Hanan, et al.
Publicado: (2020)

Lifespan Based Pharmacokinetic-Pharmacodynamic Model of Tumor Growth Inhibition by Anticancer Therapeutics
por: Mo, Gary, et al.
Publicado: (2014)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
por: McGarvey, November, et al.
Publicado: (2015)

Antibody-mediated pure red cell aplasia (PRCA) on switching from darbepoetin alfa to epoetin beta: what are the implications?
por: Assunção, José, et al.
Publicado: (2008)

Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies
por: Wish, Jay B., et al.
Publicado: (2019)

Epoetin Alfa Improves Anemia and Anemia-Related, Patient-Reported Outcomes in Patients with Breast Cancer Receiving Myelotoxic Chemotherapy: Results of a European, Multicenter, Randomized, Controlled Trial
por: Pronzato, Paolo, et al.
Publicado: (2010)

A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A “Half-and-Half” Combination Therapy()
por: Shimamatsu, Kazumasa, et al.
Publicado: (2013)

Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy
por: Fallowfield, L, et al.
Publicado: (2002)

Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients
por: Casadevall, Nicole, et al.
Publicado: (2017)

Higher‐risk myelodysplastic syndrome in an elderly patient: Long‐term partial remission with low‐dose prednisone, G‐CSF, and epoetin alfa
por: Islam, Anwarul
Publicado: (2021)

Scaling Pharmacodynamics from Rats to Humans to Support Erythropoietin and Romiplostim Combination Therapy to Treat Erythropoietin-Resistant Anemia
por: Fan, Xiaoqing, et al.
Publicado: (2023)

Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open‐label, parallel‐group, noninferiority phase III trial
por: Liu, Bicheng, et al.
Publicado: (2022)

Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open‐label, parallel‐group, non‐inferiority Phase III trail
por: Chen, Nan, et al.
Publicado: (2022)

Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
por: Donck, Jan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_u2p9ff2b60c3neovlitnkpemg1